Risk Prediction Scores for Recurrence and Progression of Non-Muscle Invasive Bladder Cancer: An International Validation in Primary Tumours

Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder

(2013) E Xylinas et al.   BRITISH JOURNAL OF CANCER

Effect of anticoagulants and antiplatelet agents on the efficacy of intravesical BCG treatment of bladder cancer: A systematic review

(2013) Nader Fahmy et al.   CUAJ-Canadian Urological Association Journal

EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013

(2013) Marko Babjuk et al.   EUROPEAN UROLOGY

Cathepsin E, Maspin, Plk1, and Survivin Are Promising Prognostic Protein Markers for Progression in Non-Muscle Invasive Bladder Cancer

(2012) Niels Fristrup et al.   AMERICAN JOURNAL OF PATHOLOGY

Combining molecular and pathologic data to prognosticate non-muscle-invasive bladder cancer

(2012) Bas W.G. van Rhijn   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

The EORTC Tables Overestimate the Risk of Recurrence and Progression in Patients with Non–Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: External Validation of the EORTC Risk Tables

(2011) Jesus Fernandez-Gomez et al.   EUROPEAN UROLOGY

Validating the EORTC risk tables in BCG-treated patients

(2011) David D. Buethe et al.   Nature Reviews Urology

A dynamic model for the risk of bladder cancer progression

(2011) Núria Porta et al.   STATISTICS IN MEDICINE

External Validity of Risk Models: Use of Benchmark Values to Disentangle a Case-Mix Effect From Incorrect Coefficients

(2010) Y. Vergouwe et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Molecular Grade (FGFR3/MIB-1) and EORTC Risk Scores Are Predictive in Primary Non–Muscle-Invasive Bladder Cancer

(2010) Bas W.G. van Rhijn et al.   EUROPEAN UROLOGY

Usefulness of the Spanish Urological Club for Oncological Treatment Scoring Model to Predict Nonmuscle Invasive Bladder Cancer Recurrence in Patients Treated With Intravesical Bacillus Calmette-Guérin Plus Interferon-α

(2010) Henry M. Rosevear et al.   JOURNAL OF UROLOGY

Statistical consideration for clinical biomarker research in bladder cancer

(2010) Shahrokh F. Shariat et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer

(2010) Virginia Hernández et al.   WORLD JOURNAL OF UROLOGY

Assessing the Performance of Prediction Models

(2009) Ewout W. Steyerberg et al.   EPIDEMIOLOGY

Prediction Models in Urology: Are They Any Good, and How Would We Know Anyway?

(2009) Andrew Vickers   EUROPEAN UROLOGY

Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model

(2009) Jesus Fernandez-Gomez et al.   JOURNAL OF UROLOGY

The development of multiple bladder tumour recurrences in relation to theFGFR3mutation status of the primary tumour

(2008) Lucie C Kompier et al.   JOURNAL OF PATHOLOGY